Prolonged twice‐daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client‐owned atopic dogs

Author:

Denti Daria1ORCID,Caldin Marco2,Ventura Laura3,De Lucia Michela1ORCID

Affiliation:

1. Dermatology Unit, San Marco Veterinary Clinic and Laboratory Via dell’Industria 3 Veggiano 35030 Italy

2. Pathology Unit San Marco Veterinary Clinic and Laboratory Via dell’Industria 3 Veggiano 35030 Italy

3. Department of Statistical Sciences University of Padova Via Cesare Battisti 241 Padova 35121 Italy

Publisher

Wiley

Subject

General Veterinary

Reference29 articles.

1. Oclacitinib ( APOQUEL ® ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

2. European Medicines Agency website. Apoquel. Available at:https://www.ema.europa.eu/en/documents/assessment‐report/apoquel‐epar‐public‐assessment‐report_en.pdf. Accessed Nov 25 2020.

3. US Food and Drug Administration. website.Apoquel FOI. Available at: Available at:https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/902. Accessed May 2 2021.

4. Long‐term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life

5. Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib

Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3